Loza Matthew J, Foster Susan, Peters Stephen P, Penn Raymond B
Department of Internal Medicine, Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
J Allergy Clin Immunol. 2008 Mar;121(3):750.e1-5.e3. doi: 10.1016/j.jaci.2007.10.036. Epub 2007 Dec 21.
Airway inflammation associated with asthma has been reported to be either unaffected or slightly increased by inhaled beta-agonist monotherapy, and concerns regarding disease exacerbations with continuous long-acting beta-agonist monotherapy have prompted the recommendation of concomitant steroid treatment.
Using peripheral blood lymphocytes from asthmatic subjects, we aimed to determine (1) whether short- or long-acting beta-agonists increase IL-13-producing (IL-13+ or IFN-gamma-producing (IFN-gamma+ T-cell numbers and (2) the ability of the corticosteroid budesonide to reverse these effects.
Peripheral blood lymphocytes from asthmatic subjects were cultured 6 days ex vivo with IL-2 and various concentrations of albuterol, formoterol, and budesonide. Numbers of IL-13+ and IFN-gamma+ T cells were determined by means of flow cytometric analysis.
Both albuterol and formoterol increased IL-2-stimulated accumulation of IL-13+ T cells, and this increase was highest at concentrations approximating the dissociation constant of each beta-agonist for the beta(2)-adrenergic receptor. Budesonide at greater than 1 nmol/L reversed the augmenting effects of beta-agonists on IL-13+ T-cell accumulation, and budesonide at greater than 10 nmol/L inhibited increases in IL-13+ T cells stimulated by IL-2. Budesonide decreased, whereas beta-agonist did not affect, numbers of total and IFN-gamma+ T cells in IL-2-stimulated cultures.
beta-Agonists at physiologically and clinically relevant concentrations stimulate increased antigen-independent, cytokine-stimulated accumulation, specifically of type 2 T cells from asthmatic subjects. The corticosteroid budesonide potently reverses this effect.
据报道,吸入性β受体激动剂单一疗法对哮喘相关的气道炎症无影响或仅有轻微增加,而对持续使用长效β受体激动剂单一疗法导致疾病加重的担忧促使人们建议联合使用类固醇治疗。
利用哮喘患者的外周血淋巴细胞,我们旨在确定:(1)短效或长效β受体激动剂是否会增加产生白细胞介素-13(IL-13+)或产生干扰素-γ(IFN-γ+)的T细胞数量;(2)皮质类固醇布地奈德逆转这些效应的能力。
将哮喘患者的外周血淋巴细胞与白细胞介素-2以及不同浓度的沙丁胺醇、福莫特罗和布地奈德在体外培养6天。通过流式细胞术分析确定IL-13+和IFN-γ+T细胞的数量。
沙丁胺醇和福莫特罗均增加了白细胞介素-2刺激的IL-13+T细胞的积累,且在接近每种β受体激动剂与β2肾上腺素能受体解离常数的浓度下,这种增加最为显著。浓度大于1 nmol/L的布地奈德可逆转β受体激动剂对IL-13+T细胞积累的增强作用,浓度大于10 nmol/L的布地奈德可抑制白细胞介素-2刺激的IL-13+T细胞的增加。布地奈德可减少白细胞介素-2刺激培养物中总T细胞和IFN-γ+T细胞的数量,而β受体激动剂则无此影响。
在生理和临床相关浓度下,β受体激动剂可刺激哮喘患者2型T细胞抗原非依赖性、细胞因子刺激的积累增加。皮质类固醇布地奈德可有效逆转这种效应。